CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
about
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerAcquired and intrinsic resistance in cancer immunotherapyPathways and therapeutic targets in melanoma4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityTumor infiltrating lymphocytes in ovarian cancerCD137 and CD137L signals are main drivers of type 1, cell-mediated immune responsesPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response.Current advances in T-cell-based cancer immunotherapyEfficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinomaA fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.Advances and prospects in adoptive cell transfer therapy for ovarian cancerTumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy.CD137 is a Useful Marker for Identifying CD4+ T Cell Responses to Mycobacterium tuberculosis.Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.Triggering co-stimulation directly in melanoma tumor fragments drives CD8(+) tumor-infiltrating lymphocyte expansion with improved effector-memory properties.Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.Finding a needle in a haystack: Activation-induced CD137 expression accurately identifies naturally occurring tumor-reactive T cells in cancer patients.Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma.Immuno-oncology combinations: raising the tail of the survival curve.Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation.Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy.Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis.CD137-CRDI is not necessary in the role of contacting its natural ligand.S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.Anticalin® Proteins as Therapeutic Agents in Human Diseases.Bispecific antibodies in cancer immunotherapyAdoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment optionCo-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
P2860
Q26780387-E0CF3C62-9FFA-458D-8BCD-FDE93DDC4FF1Q26827701-583E6639-AB22-4E4E-9A39-5BB4131F7128Q26865736-0A79C1C1-146E-4601-BBCE-37FA98F51AAEQ27012963-D4BCB523-395D-4CCA-89CE-8F035E70715BQ27021878-AF2EE996-B2C4-444E-9841-5694AA81E6E0Q28072933-1C25B882-FFB2-4E90-ABE0-1334C1DCC44DQ34550012-FDC81BE4-4B5A-4DF7-BE71-F681CE40B855Q34781308-ADA7C6CE-703D-46E2-91F1-07A491E9FBE5Q35215158-5E1FFD66-21B0-44AF-BBA0-0020D81D67F0Q35677962-C1E0B28E-2BF0-41AB-8B09-CC64E21D2FBFQ36356392-A505CDE1-ACE1-4A4D-889F-7FE09BFAC5F5Q36852332-ECF6F961-D391-4D48-B47C-263374DA2C0BQ37320131-B64B6678-2857-4ED0-84FB-8AE7EA4A8416Q37489634-4BF99099-1222-4FBB-92FF-9890D5890D47Q37688907-FE22F975-5638-4999-A1C8-93E9D0339233Q37726682-6C566D9A-E8A8-4268-8505-6A4E667D8430Q38223594-BEC9C6EF-84A2-4C52-8CA8-818CDBFFAC38Q38636573-1C348597-F10A-48CA-AECE-94F9D7EF4503Q38665128-7FD8472A-8D52-4399-8ACC-34F8F3A765F3Q38784018-47E9824C-CAE7-4DD8-BE6E-D2E45F1F9DABQ40325377-74D5CDC4-41F9-4419-9CC4-B9E81B2F8718Q40774020-A5778521-AD45-4A67-8DFF-74F978DA6212Q41807501-F2642684-B431-4B0E-A21F-A3033404C18CQ41911091-7AB88095-E3C3-4941-9535-96E5987425A9Q41915705-F81B4AD4-B6FC-4C58-ABDD-FB280075C005Q42078847-522E52E1-3E9F-4ADC-97DA-50DED4C9F840Q42421273-E054A697-D4D3-4A15-855F-27450B6F150EQ42654278-F8ED01F1-1ADF-49B7-866C-BB4707C672BCQ42695489-C62157F5-64B4-416B-AC51-2924671999E6Q43129884-05A3BA35-A986-4D5D-AD52-FA14877DA8D7Q46047154-1346710F-D8E8-43E4-97B6-E7380D2364EAQ47335259-39D494BF-F3A7-43EA-8AD3-EFFD7EE63F99Q47950137-F085F62B-B710-4FB7-ABA4-88E9D7487BD9Q49185666-96598DA7-39E0-41EB-8A7E-ABE8F0C95643Q50783362-62A8B87E-1DBD-43A6-97F6-C65523E80BBBQ52597566-5A3D2C12-65E8-430B-8E9F-00FEC731B7FBQ55484632-ADBF4EEE-22FF-4C7C-B78E-A55A3C7C673DQ56893015-5B9117DB-0064-4003-8C3C-116AE4EF50C9Q57038247-0EB1F1BA-5ADF-4BE3-8220-CEEAF4941B98Q57176182-39AFB7CC-ABF8-4B64-B47C-6E85241E0C7E
P2860
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@ast
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@en
type
label
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@ast
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@en
prefLabel
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@ast
CD137 accurately identifies an ...... mor-reactive T cells in tumor.
@en
P2093
P2860
P1476
CD137 accurately identifies an ...... umor-reactive T cells in tumor
@en
P2093
Andrew Best
Chunsheng Li
Daniel J Powell
De-Gang Song
Mathilde Poussin
Tori Yamamoto
P2860
P356
10.1158/1078-0432.CCR-13-0945
P407
P577
2013-09-17T00:00:00Z